- Home
- MGRX vs SLXN Comparison
MGRX vs SLXN Comparison
Compare MGRX & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- SLXN
- Stock Information
- Founded
- MGRX 2021
- SLXN 2008
- Country
- MGRX United States
- SLXN Israel
- Employees
- MGRX N/A
- SLXN N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- SLXN
- Sector
- MGRX Technology
- SLXN
- Exchange
- MGRX Nasdaq
- SLXN NYSE
- Market Cap
- MGRX 6.3M
- SLXN 5.2M
- IPO Year
- MGRX 2023
- SLXN N/A
- Fundamental
- Price
- MGRX $2.55
- SLXN $2.74
- Analyst Decision
- MGRX
- SLXN Strong Buy
- Analyst Count
- MGRX 0
- SLXN 1
- Target Price
- MGRX N/A
- SLXN $1.00
- AVG Volume (30 Days)
- MGRX 59.1K
- SLXN 1.9M
- Earning Date
- MGRX 11-14-2024
- SLXN 11-14-2024
- Dividend Yield
- MGRX N/A
- SLXN N/A
- EPS Growth
- MGRX N/A
- SLXN N/A
- EPS
- MGRX N/A
- SLXN N/A
- Revenue
- MGRX $755,000.00
- SLXN N/A
- Revenue This Year
- MGRX N/A
- SLXN N/A
- Revenue Next Year
- MGRX N/A
- SLXN N/A
- P/E Ratio
- MGRX N/A
- SLXN N/A
- Revenue Growth
- MGRX 52.20
- SLXN N/A
- 52 Week Low
- MGRX $2.10
- SLXN $0.21
- 52 Week High
- MGRX $16.80
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- MGRX 53.52
- SLXN N/A
- Support Level
- MGRX $2.44
- SLXN N/A
- Resistance Level
- MGRX $2.62
- SLXN N/A
- Average True Range (ATR)
- MGRX 0.12
- SLXN 0.00
- MACD
- MGRX 0.02
- SLXN 0.00
- Stochastic Oscillator
- MGRX 96.30
- SLXN 0.00
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.